DOTTIKON EXCLUSIVE SYNTHESIS AG manufactures exclusive active pharmaceutical ingredients (APIs), high-quality intermediates and performance chemicals for the world's leading chemical and pharmaceutical industry.

The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and is positioned as strategic development and manufacturing partner. Its safety culture created over the last 100 years guides innovative uses of hazardous reactionslow-temperature and high-pressure chemistry, as well as continuous processing. This shortens conventional chemical synthesis routes, increases yields, selectivities and purities, and reduces waste. The versatile technology and equipment portfolio is used to design, develop and optimize chemical processes, and scale up from kilograms to multi-tons.

DOTTIKON's one-site strategy allows reduced decision and communication pathways, thus ensuring rapid and efficient project development as well as clear and transparent communication with customers.


DOTTIKON EXCLUSIVE SYNTHESIS AG's roots date back to 1913, when the company was founded under the name of Schweizerische Sprengstoff-Fabrik AG (SSF), a specialist in explosives.

From the 1930s to the 1970s, SSF developed processes for nitration, hydrogenation and oxidation, which evolved into the chemical intermediates business and the production based hazardous chemical reactions that the company still excels in today. In 1987, Ems-Chemie Holding AG purchased the company and changed its name to EMS-Dottikon in 1990. Amid a spin-off from Ems-Chemie Holding in 2005, the company received its current name, DOTTIKON EXCLUSIVE SYNTHESIS AG, and the parent company DOTTIKON ES HOLDING AG's shares went public in an IPO in the main segment of the SIX Swiss Exchange on March 31 of the same year. In 2013, the company celebrated its 100-year anniversary.


Photo documentation 100 years DOTTIKON

Research and development laboratory, 1918

Research and development laboratory, 1918


Half of net sales with APIs


20.03.–23.03.2017  DCAT Week 2017


New York City, NY, USA

The Lexington New York, Suite no 2015




16.05.–18.05.2017  InformEx 2017


Philadelphia, PA, USA

Pennsylvania Convention Center, Booth no 2013




31.05.–01.06.2017  Chemspec Europe 2017


Munich, Germany

Munich Trade Fair Centre, Hall A6, Booth no E190


Organization & Management

DOTTIKON EXCLUSIVE SYNTHESIS AG is an entity of SIX-listed DOTTIKON ES HOLDING AG. The stable senior management and shareholder structure of the DOTTIKON ES Group enables sustainable value growth at the manufacturing site in Dottikon, Switzerland.

Board of Directors

  • Dr. Markus Blocher (Chairman)
  • Dr. Thomas Früh (Deputy Chairman)
  • Dr. Alfred Scheidegger


Senior Management

  • Dr. Markus Blocher (CEO)
  • Marlene Born (CFO)
  • Dr. Stephan Kirschbaum (Head of Business Development)
  • Dr. Max Bachmann (Head of Processes & Technologies)
  • Dr. Thomas Rosatzin (Head of Purchasing)
  • Bruno Eugster (Head of Production)
  • Dr. Knut Hildebrandt (Head of Quality Management)


DOTTIKON is organized around the main processes business and process development, purchasing, production and quality management.

The production facility is located on approximately 600'000 m² in Dottikon (Switzerland), close to Basel and Zurich. About 100'000 m² of the premises are reserved for development of customer-driven production facilities.

Chairman and CEO Markus Blocher

Chairman and CEO Markus Blocher


DOTTIKON's headquarters are located in Dottikon, Switzerland.


Headquarters Switzerland


Dottikon Exclusive Synthesis AG                  

Hembrunnstrasse 17

5605 Dottikon



Tel+41 56 616 81 11
Fax  +41 56 616 81 20




View map



Representative Office US


Dottikon ES America, Inc.
803 W. Trenton Avenue, Suite 1
Morrisville, PA 19067
United States


Tel+1 215 295 2295
Fax  +1 215 295 2577




View map